Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

SPM-927 (Schwarz Pharma).

Collin A Hovinga1

  • 1The Cleveland Clinic Foundation, Departments of Neurology/Pharmacy, 9500 Euclid Ave-S51, Cleveland, OH 44195, USA. cahovinga@aol.com

Idrugs : the Investigational Drugs Journal
|June 6, 2003
PubMed
Summary

Schwarz Pharma is developing SPM-927 for epilepsy and neuropathic pain. This novel compound, synthesized at the University of Houston, shows potential for treating these neurological conditions.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating Kidney Function Decline in Children with Chronic Kidney Disease Using a Multi-Institutional Electronic Health Record Database.

Clinical journal of the American Society of Nephrology : CJASN·2023
Same author

Efficacy and patient opinion of wet-wrap dressings using 0.1% triamcinolone acetonide ointment vs cream in the treatment of pediatric atopic dermatitis: A randomized split-body control study.

Pediatric dermatology·2019
Same author

Association Between Delusions of Infestation and Prescribed Narcotic and Stimulant Use.

Journal of psychiatric practice·2018
Same author

Thrombolysis in pediatric stroke study.

Stroke·2015
Same author

Emergence of the primary pediatric stroke center: impact of the thrombolysis in pediatric stroke trial.

Stroke·2014
Same author

Epigenetic analysis of neurocognitive development at 1 year of age in a community-based pregnancy cohort.

Behavior genetics·2014

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Epilepsy and neuropathic pain are significant unmet medical needs.
  • Current treatments have limitations in efficacy and side effect profiles.

Purpose of the Study:

  • To introduce SPM-927 as a potential therapeutic agent.
  • To highlight its development for epilepsy and neuropathic pain.

Main Methods:

  • SPM-927 synthesized by researchers at the University of Houston.
  • Development licensed by Schwarz Pharma from Harris FRC.

Main Results:

  • SPM-927 demonstrates potential for treating epilepsy.
  • SPM-927 shows promise for neuropathic pain management.

Conclusions:

  • SPM-927 represents a promising new candidate for neurological disorder treatment.
  • Further research and clinical trials are warranted to establish its efficacy and safety.